Rezolute Reports Positive Expanded Phase 3 Data for Ersodetug in Congenital HI; FDA Encourages Submission
Summary
Rezolute reported positive expanded Phase 3 data for its lead drug ersodetug in congenital HI, showing significant glycemic improvements, with the FDA encouraging comprehensive data submission for evaluation.
Key Events
-
Positive Expanded Phase 3 Data
Expanded analyses from the Phase 3 sunRIZE study for ersodetug in congenital HI showed significant and consistent improvements in glycemic control, including >50% reductions in daily percent time in hypoglycemia and ~50-80% reductions in weekly hypoglycemia events by CGM.
-
FDA Encourages Data Submission
Following a Type B meeting, the FDA encouraged Rezolute to submit comprehensive analysis datasets and summary outcomes for the agency's independent evaluation, acknowledging challenges in measuring hypoglycemia in this patient population.
-
Q3 Fiscal 2026 Financial Results
The company reported a net loss of $16.2 million for the third quarter of fiscal 2026, a narrower loss compared to $18.9 million in the prior year period. Cash, cash equivalents and investments stood at $120.3 million as of March 31, 2026.
-
Tumor HI Study Ongoing
The Phase 3 upLIFT study for tumor HI is ongoing, with topline results expected in the second half of 2026.
Analysis
Rezolute announced detailed positive expanded analyses from its Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism (HI), demonstrating significant and consistent improvements in glycemic control across multiple CGM-based outcomes. This includes substantial reductions in hypoglycemia events and increased time in normoglycemia. Crucially, the FDA encouraged the company to submit comprehensive data for independent evaluation, providing a potential path forward for the drug despite earlier primary endpoint challenges. While the company reported a Q3 net loss of $16.2 million, the clinical and regulatory update is the primary market-moving information, offering renewed optimism for its lead candidate.
At the time of this filing, RZLT was trading at $3.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $315.8M. The 52-week trading range was $1.07 to $11.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.